|
Barrett JS, Szego P, Rohatagi S, Morales RJ, De Witt KE, Rajewski G, Ireland J. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res. 1996 ;13:1535-40.
Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study J Neural Transm. 1985;64:113-27
Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977 ;1:439-43.
Brecht ML, O'Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences.Addict Behav. 2004 ;29:89-106.
Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998 ;32:117-31. Review
Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO, Miyasaka K. Long term treatment with (-)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sci. 1996;59:1047-57.
Chapman DE, Hanson GR, Kesner RP, Keefe KA. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. Pharmacol Exp Ther 2001;296:520–7.
Chiueh CC, Huang SJ, Murphy DL Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity J Neural Transm Suppl. 1994;41:189-96
Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001 ;36:1-22
Deakin JFW, Dostrovsky JA. Involvement of the periaqueductal
grey matter and spinal 5-hydroxytryptaminergic pathways in morphine
analgesia: effects of lesions and 5-hydroxytryptamine depletion.
Br J Pharmacol.1978; 63:159–165.
de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schroder N. Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol. 2005 ;40:506-11.
Freisleben HJ, Lehr F, Fuchs J. Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm Suppl. 1994; 41:231-6
Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol. 1997 ;334:273-9
Friedman SD, Castaneda E, Hodge GK. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1998; 61:35–44.
Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. A
single dose of methamphetamine-induced neurotoxicity in rats: effects
on neostriatal monoamines and glial fibrillary acidic protein.
Brain Res.1998; 806:1–7.
Gallagher IM, Clow A, Glover V. Long-term administration of (-)-deprenyl increases mortality in male Wistar rats. J Neural Transm Suppl. 1998;52:315-20
Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacol Biochem Behav. 2004 ;79:751-60.
Gibb JW, Kogan FJ. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol. 1979 ;310:185-7
Guilarte TR, Nihei MK, McGlothan JL, Howard AS. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience. 2003;122:499-513.
Heinonen EH, Myllyla V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijarvi M, Kotila M, Rinne UK. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand Suppl. 1989;126:93-9.
Huang YH, Yu CM, Chen CT. Evidence that deprenyl reverse methamphetamine-induced reduction of the local cerebral glucose utilization of the orbitofrontal cortex in rats. Submitted in 2006
Iwazaki T, McGregor IS, Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res. 2006;1097:19-25.
Jayanthi S,Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J. 2004 ;18:238-51.
Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 1993;52:281-8.
Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev. 1988 ;46:237-62
Knoll J, Miklya I. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Arch Int Pharmacodyn Ther. 1994 ;328:1-15.
Kogan FJ, Nichols WK, Gibb JW. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels Eur J Pharmacol. 1976 ;36:363-71
LaVoie MJ,Card JP,Hastings TG. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol. 2004 ;187:47-57
Lovick TA. Influence of the dorsal and median raphe nuclei on
neurons in the periaqueductal gray matter: role of 5-hydroxytryptamine.
Neuroscience,1994; 59:993–1000.
Lucot JB, Wagner GC, Schuster CR, Seiden LS. The effects of dopaminergic agents on the locomotor activity of rats after high doses of methylamphetamine. Pharmacol Biochem Behav. 1980 ;13:409-13.
Magyar K, Lengyel J, Szatmari I, Gaal J. The distribution of orally administered (-)-deprenyl-propynyl-14C and (-)-deprenyl-phenyl-3H in rat brain Prog Brain Res. 1995;106:143-53.
Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of (-)-deprenyl. Curr Med Chem. 2004 ;11:2017-31. Review
Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004 ;25:233-42. Review
Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Acad Sci Hung. 1967;32:377-87
Miczek KA, Nikulina E, Kream RM, Carter G, Espejo EF. Behavioral
sensitization to cocaine after a brief social defeat stress:
c-fos expression in the PAG. Psychopharmacology,1999, 141:225–234.
Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance on L-deprenyl prolongs life in aged male rats Life Sci. 1990;47:415-20
Mood I, Marinac JS, Willsie S, Mason WD. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers Biopharm Drug Dispos. 1995 ;16:535-45
Ourednik J,Ourednik V,Lynch WP, Schachner M, Snyder EY. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol. 2002 ;20:1103-10.
Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 1982 ;235:93-103
Samanin R, Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993 ;73:63-8.
Schroder N, O'Dell SJ, Marshall JF. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse. 2003 ;49:89-96.
Segal, D.S., Kuczenski, R. Behavioral pharmacology of
amphetamine. In: Cho, A.K., Segal, D.S. (Eds.), Amphetamine
and its analogs: psychopharmacology, toxicology and abuse. 1994. Academic, San Diego, pp. 115–150.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 ;51:604-12
Shinba T, Yamamoto K, Cao GM, Mugishima G, Andow Y, Hoshino T. Effects of acute methamphetamine administration on spacing in paired rats: investigation with an automated video-analysis method. Prog Neuropsychopharmacol Biol Psychiatry. 1996 ;20:1037-49.
Sumiyoshi T, Tsunoda M, Uehara T, Tanaka K, Itoh H, Sumiyoshi C, Kurachi M. Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: behavioral and in vivo microdialysis studies. Neurosci Lett. 2004 ;364:124-9.
Suzuki T, Fukuoka Y, Mori T, Miyatake M, Narita M. Behavioral sensitization to the discriminative stimulus effects of methamphetamine in rats. Eur J Pharmacol. 2004 ;498:157-61.
Tanaka M, Nagashima K, McAllen RM, Kanosue K. Role of the
medullary raphe in thermoregulatory vasomotor control in rats.
J Physiol.2002; 540:657–664.
Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism J Neurosci Res. 1991 ;30:666-72.
Wagner GC, Seiden LS, Schuster CR. Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs.
Drug Alcohol Depend. 1979 ;4:435-8.
Widdowson PS, Griffiths EC, Slater P. Body temperature effects
of opioids administered into the periaqueductal grey area of rat
brain. Reg Peptides.1983; 7:259–267.
Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol. 1993 ;243:241-7.
Yasar S, Gaal J, Panlilio LV, Justinova Z, Molnar SV, Redhi GH, Schindler CW. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology (Berl). 2006 ;183:413-21
Yen TT, Knoll J. Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L.) and (-)deprenyl. Acta Physiol Hung. 1992;79:119-24.
|